|
Therion Biologics Investors
Therion has raised over $100 million in equity funding for the advancement of its lead therapeutic cancer programs in prostate cancer, pancreatic cancer, and melanoma. Therion is also applying its technology platform to develop vaccines to treat breast cancer and other solid tumors. Together with Aventis Pasteur, the Company is developing immunotherapy products for colorectal cancer and melanoma. For more information about Therion and its cancer vaccine programs, please contact George Eldridge, Senior Vice President, Chief Financial Officer, at 617-475-7212.
Therion�s lead institutional investors include:
- BioVentures Investors
- CDP Capital Technology Ventures
- H&Q Healthcare Investors
- H&Q Life Sciences Investors
- Kranich GmbH
- Loeb Investors
- New York Life Insurance Company
- Northwood Ventures
- Pacific Horizon Ventures
- S.R. One Limited
- Singapore Bio-Innovations
- Venture Capital Fund of America
|
|
